TY - JOUR T1 -支气管扩张剂在哮喘和COPD中的可逆性:发现三大人口研究摩根富林明-欧洲呼吸杂志》乔和J - 10.1183/13993003.00561 -2019欧元六世- 54 - 3 SP - 1900561 AU -延森Christer盟——Malinovschi安德烈•AU - Amaral安德烈F.S.盟——Accordini西蒙AU - Bousquet,让非盟- Buist博士,a .索尼亚盟——Canonica乔治•沃尔特盟——DahlenBarbro AU - Garcia-Aymerich, Judith AU - Gnatiuc, Louisa AU - Kowalski, Marek L AU - Patel, Jaymini AU - Tan, Wan AU - Torén, Kjell AU - Zuberbier, Torsten AU - Burney, Peter AU - Jarvis，Deborah Y1 - 2019/09/01 UR - //www.qdcxjkg.com/content/54/3/1900561.abstract N2 -支气管扩张剂反应(BDR)试验被用作阻塞性气道疾病的一种诊断方法。本研究的目的是比较哮喘和慢性阻塞性肺病(COPD)患者BDR测量的不同方法，并研究BDR与症状负担和表型特征的相关程度。在3项大型国际人口研究中，35 628名年龄≥16岁的受试者在服用200 μg沙丁胺醇前和15分钟后测量了1秒用力呼气量(FEV1)和用力肺活量(FVC)。研究对象被分为三组:当前哮喘(n=2833)、COPD (n=1146)和无气道疾病(n= 31649)。血流相关可逆性的三个定义(FEV1的增加)和体积相关可逆性的三个定义(FVC的增加)被使用。哮喘和COPD患者的FEV1增加≥12%和200 mL表示的支气管扩张剂可逆性患病率分别为17.3%和18.4%，而在无气道疾病的患者中相应患病率为5.1%。在哮喘中，支气管扩张剂可逆性与喘息(OR 1.36, 95% CI 1.04-1.79)、特应性(OR 1.36, 95% CI 1.04-1.79)和较高的呼出一氧化氮分数相关，而在COPD中，与流量或容量相关的支气管扩张剂可逆性与症状负担无关。调整支气管扩张剂前FEV1后的病情加重或健康状况。Bronchodilator reversibility was at least as common in participants with COPD as those with asthma. This indicates that measures of reversibility are of limited value for distinguishing asthma from COPD in population studies. However, in asthma, bronchodilator reversibility may be a phenotypic marker.Bronchodilator reversibility is at least as common in COPD as in asthma, indicating that measures of reversibility are of limited value for distinguishing asthma from COPD; however, bronchodilator reversibility in asthma may be a phenotypic marker. http://bit.ly/2W1oA4B ER -